Related Experiment Video
Updated: Mar 26, 2026
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Indications for biopsy and the current status of focal therapy for renal tumours
Ricardo R N Leão1, Patrick O Richard1, Michael A S Jewett1
1Department of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, Ontario, Canada.
Abstract:
The increased detection of small renal masses (SRMs) has focused attention on their uncertain natural history. The development of treatment alternatives and the discovery of biologically targeted drugs have also raised interest. Renal mass biopsies (RMBs) have a crucial role as they provide the pathological, molecular and genetic information needed to classify these lesions and guide clinical management. The improved accuracy has improved our knowledge of the behaviour of different tumour histologies and opened the potential for risk-adapted individualized treatment approaches. To date, studies have demonstrated that percutaneous ablation is an effective therapy with acceptable outcomes and low risk in the appropriate clinical setting. Although partial nephrectomy (PN) is still considered the standard treatment for SRM, percutaneous ablation is increasingly being performed and if long-term efficacy is sustained, it may have a wider application for SRMs after biopsy characterization.
Insights
Renal mass biopsies (RMBs) help classify small renal masses (SRMs). Percutaneous ablation shows promise as an effective alternative to partial nephrectomy (PN) for SRMs, potentially guiding individualized treatment.
Area of Science:
- Urology
- Oncology
- Pathology
Background:
- Increased detection of small renal masses (SRMs) necessitates understanding their natural history and treatment options.
- Biologically targeted drugs and novel therapies are emerging for renal lesions.
- Renal mass biopsies (RMBs) are vital for classifying SRMs and guiding management.
Purpose of the Study:
- To highlight the critical role of RMBs in characterizing SRMs.
- To review the efficacy and safety of percutaneous ablation for SRMs.
- To discuss the potential of risk-adapted treatment strategies for SRMs.
Main Methods:
- Review of current literature on small renal masses, renal mass biopsies, and percutaneous ablation.
- Analysis of pathological, molecular, and genetic information obtained from RMBs.
- Evaluation of outcomes for percutaneous ablation versus traditional partial nephrectomy (PN).
Main Results:
- Improved RMB accuracy enhances understanding of tumor behavior and histology.
- Percutaneous ablation is an effective therapy for SRMs with acceptable outcomes and low risk in selected cases.
- Partial nephrectomy (PN) remains the standard, but percutaneous ablation is gaining traction.
Conclusions:
- RMBs are essential for classifying SRMs and enabling risk-adapted, individualized treatment.
- Percutaneous ablation is a viable and effective treatment option for SRMs.
- Long-term data may support wider application of percutaneous ablation for SRMs post-biopsy.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:28Chronic Kidney Disease III: Interprofessional Care